[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delivery-of-health-care\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delivery-of-health-care":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,63,104,131,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":38,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100635793","supporting-just-in-time-consent-for-prenatal-screening-the-inform-study-100635793",false,"NCT07557303","Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study","Inclusion Criteria:\n\n* Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.\n* 18 years of age and older\n* Able to read, speak, and understand English or Spanish\n* Has not previously been offered prenatal genetic screening for the current pregnancy\n* 24 weeks (6 months) gestational age or less\n\nExclusion Criteria:\n\n* Not pregnant, not a patient at a partner clinical site\n* Younger than 18 years of age\n* Not being able to read, speak, and understand English or Spanish\n* Has previously been offered prenatal genetic screening for the current pregnancy\n* Greater than 24 weeks gestational age (6 months)",true,"FEMALE","18 Years",{"count":19,"type":20},1400,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.\n\nThe study has one main question:\n\n* Do participants who use the intervention feel more confident when they make a decision about screening?\n\nResearchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.\n\nWhat will participants do?\n\n* Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.\n* Some participants will use the intervention before their first doctor's visit. Other participants will not use it.\n* All participants will talk with a researcher on the phone after their first doctor's visit.\n* Participants who use the intervention will answer a short survey on their phone.\n* A few participants who use the intervention will talk with a researcher a second time on the phone.",[26,27,28,29,30,31,32,33,34,35,36,37],"Delivery of Health Care","Genetic Testing","Humans","Pregnancy","Noninvasive Prenatal Testing","Informed Consent","Internet-Based Intervention","Self Efficacy","Pregnant People","Decision Making","Health Education","Patient Education as Topic\u002FMethod",[39,40,41,42,43,44,45,46,47,48,49],"Non-invasive prenatal screening (NIPS)","Non-Invasive Prenatal Testing (NIPT)","Cell-free DNA (cfDNA)","Prenatal genetic screening","Informed consent","Decision making","Surveys and Questionnaires","Informed choice","Educational intervention","Decision Regret","Decision Satisfaction","NOT_YET_RECRUITING","2026-06-30",{"date":53,"type":54},"2026-07-01","ACTUAL",{"date":56,"type":20},"2026-08-01",{"date":58,"type":20},"2028-06-30",{"name":60,"class":61},"Case Western Reserve University","OTHER",3,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":103},"100557582","advancing-decisions-about-virtual-service-encounters-100557582","NCT06539988","Advancing Decisions About Virtual Service Encounters","Advancing Decisions About Virtual Service Encounters (ADViSE)","ADViSE","Inclusion Criteria:\n\n* Veteran inclusion criteria are having an upcoming face-to-face (F2F), telephone, or VA Video Connect (VVC) appointment in the next 8 to 12 weeks\n* Having at least 3 Primary Care F2F, telephone, or VVC encounters in the previous 12 months\n* Able to provide informed consent\n* Willing and able to receive text messages from the VA Patient Engagement, Tracking, and Long-term Support (PETALS) platform\n\nExclusion Criteria:\n\n* Veteran exclusion criteria are a CDW diagnosis of mild cognitive impairment, dementia, or a psychotic disorder","ALL",{"count":73,"type":20},600,[23],"Expanded availability of virtual care encounters in Primary Care provides new opportunities to improve Veterans' outcomes by aligning encounter modalities with their needs and preferences. Yet, Veterans and their Primary Care physicians (PCPs) lack personalized information about the benefits and costs of different Primary Care modalities that is needed to maximize the value of Primary Care encounters. To address this problem, in this study the investigators will use surveys and interviews to identify what Veterans and PCPs perceive to be the benefits and optimal uses of different Primary Care encounter modalities. They will then supplement their existing system for communicating encounter costs to Veterans and PCPs with new interactive messaging about benefits and optimal uses of different encounter modalities. Finally, this novel Advancing Decisions about Virtual Service Encounters (ADViSE) intervention will be optimized through user-centered refinement before evaluating its effects on Veteran-centered outcomes, use of virtual care, and intermediate health outcomes in a randomized controlled trial (RCT).",[77,26],"Health Care Costs",[79,80,81,82,83,84,85,86,87,88,89,90,91,92],"Access","Behavior (patient)","Behavior (provider)","Rural Health","Patient preferences","Decision support","Telemedicine","Patient-centered Care","Communication (doctor-patient)","Cost","Patient outcomes","Primary care","Satisfaction (patient)","Virtual care","RECRUITING","2026-04-02",{"date":96,"type":54},"2026-04-08",{"date":98,"type":54},"2026-04-01",{"date":58,"type":20},{"name":101,"class":102},"VA Office of Research and Development","FED",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":71,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100504547","breaking-disparities-in-access-to-advanced-diabetes-technologies-in-children-with-type-1-diabetes-100504547","NCT05849753","Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes","Breaking Health Care Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes","Inclusion Criteria:\n\nDiagnosis of T1D for at least 1 year based on clinical presentation (polyuria, polydipsia, weight loss, and\u002For ketoacidosis, or with positive diabetes autoantibodies) on insulin, including injections or open-loop pumps\n\n* HbA1C ≥ 8.0% at least twice within the last 12 months before study initiation, upper limit of HbA1C \\\u003C14%\n* Be of lower SES, defined based on \\\u003C 200% above published US levels of poverty by family size and income, or based on exceptional circumstantial needs in the opinion of the investigators\n* Approximately 1\u002F3 AA, 1\u002F3 Hispanic\u002FLatinos, 1\u002F3 non-Hispanic whites. Asians, Pacific Islanders and other ethnic groups however will not be excluded from participation if other criteria met\n* History of hypothyroidism on adequate replacement therapy with normal thyroid function will be allowed\n\nExclusion Criteria:\n\n* Severe eczema or any other skin condition that would limit availability of healthy skin to wear devices\n* Chronic medications\u002Fmedical conditions that could interfere with diabetes management (ADHD medications allowed)\n* Chronic seizures, or severe neurodevelopmental delay\n* Current use of hybrid closed-loop, automated insulin delivery system\n* Significant mental health disorder that in opinion of the investigator would hinder device use","6 Years","17 Years",{"count":114,"type":20},50,"OBSERVATIONAL","50 children\u002Fadolescents (ages 6 to \\\u003C18yrs) with T1D in suboptimal control (HbA1c≥8.0%) and lower SES (below 200% poverty line) on insulin therapy (either injections or open-loop pumps) will be recruited at Nemours \\~ 1\u002F3 each AA, Hispanic\u002FLatino, non-Hispanic whites. All families that qualify and agree to transition to closed-loop technologies will be recruited to allow data to be gathered before and after use of devices. They will go through the process of approval with the assistance of an insurance navigator in clinic. Those not a CGM will be prescribed one as well. Diabetes care will be 'real life', devices will be prescribed, and care per clinic routine with periodic device downloads. Principal outcome, time-in-range, will be analyzed at 3-months compared to baseline, each participant their own control. Secondary outcomes including HbA1c, other glucose metrics and questionnaires related to use of technology and diabetes distress will be also analyzed. All outcomes will also be collected at 6-months. Results could have important and fast applicability to the field and help better inform decision makers, including payers, clinicians, and patients and families and could serve to decrease health care disparities in this needy population.",[118,119,26,120],"Diabetes Mellitus, Type 1","Child","Equipment and Supplies","2026-02-19",{"date":123,"type":54},"2026-02-23",{"date":125,"type":54},"2023-07-26",{"date":127,"type":20},"2026-12-31",{"name":129,"class":61},"Nemours Children's Clinic",2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":164,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":103},"100585650","digital-transformation-of-continuity-of-care-for-peripherally-inserted-central-catheters-spadcare-experience-100585650","NCT06905119","Digital Transformation of Continuity of Care for Peripherally Inserted Central Catheters: SpadCare Experience","SpadCare","Inclusion Criteria:\n\n* Patients \\>18 years.\n* Sign the informed consent form.\n* Have a Smartphone and accept the use of the APP.\n* Patient with a PICC inserted by the Infusion and Vascular Access Team of the University Hospital of Navarra and with a planned use of at least one month.\n\nExclusion Criteria:\n\n* Patients with limitations in the use of digital resources or lack of Smartphone.\n* Patients who do not want to install the APP on their Smartphone\n* Patients who do not authorize access to their Computerized Medical Record (HCI).",{"count":139,"type":20},201,[23],"The study focuses on patients who require outpatient infusion of therapy (\"Infusions, Intravenous\"\\[Mesh\\]) \"Administration, Intravenous\"\\[Mesh\\] (\"Home Infusion Therapy\"\\[Mesh\\]) \"Parenteral Nutrition, Home\"\\[Mesh\\] via a peripherally inserted central catheter (PICC) (\"Central Venous Catheters\"\\[MeSH\\] \"Catheterization, Central Venous\"\\[MeSH\\] \"Catheterization, Peripheral\" \\[MeSH\\] \"Vascular Access Devices\"\\[Mesh\\] )",[143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,26,160,161,162,163,85],"Infusions, Intravenous","Administration, Intravenous","Home Infusion Therapy","Parenteral Nutrition, Home","Central Venous Catheters","Catheterization, Central Venous","Catheterization, Peripheral","Vascular Access Devices","Patient Education as Topic","Patient Participation","User-Computer Interface","Smartphone","Mobile Applications","Computers, Handheld","Digital Health","Nursing","Care Givers","Home Nursing","Self Administration","Adverse Effects","Catheter-Related Infections",[149,150,151,85,155],"2025-09-11",{"date":167,"type":54},"2025-09-12",{"date":169,"type":54},"2023-05-04",{"date":171,"type":20},"2026-07-31",{"name":173,"class":61},"Fundacion Miguel Servet",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":103},"100572812","differentiated-service-delivery-dsd-for-people-living-with-hiv-plhiv-and-comorbidities-100572812","NCT06738134","Differentiated Service Delivery (DSD) for People Living with HIV (PLHIV) and Comorbidities","Implementation of Differentiated Service Delivery Model of Care for People Living with HIV with Comorbidities","Inclusion Criteria:\n\n* PLWH eligible to participate in this study are PLWH aged 18 years or above\n* followed up at the HIV Clinic, and with one or more cardiometabolic comorbidities, including hypertension, diabetes, hyperlipidaemia, metabolic-associated fatty liver disease, cardiovascular diseases, and cerebrovascular diseases. They will be eligible if HIV physicians consider them having sub-optimal control of their comorbidities, suspected of having complications, or would benefit from screening of complications resulting from their comorbidities. These indications are selected as they involve specialist care, including investigations and treatment, which are not available at the HIV Clinic.\n\nExclusion Criteria:\n\n* Incompetent subjects who cannot give informed written consent.",{"count":182,"type":20},300,"This is an implementation study evaluating differentiated service delivery model for the care of comorbidities for people living with HIV (PLWH). The Hybrid Type 3 study design is adopted, with the primary goal of evaluating implementation outcomes, and secondary goals of evaluating service and client outcomes according to the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework, including Proctor's Conceptual Framework for Implementation Outcomes, using mixed methods for data collection and analyses. PLWH will be identified from the Integrated Treatment Centre, an HIV clinic in Hong Kong, which provides care to around 3500 PLWH, with services including out-patient care of patients with human immunodeficiency virus (HIV) infection, antiviral therapy for HIV and hepatitis co-infection, and treatment of sexually transmitted diseases. PLWH with comorbidities will be asked to participate in a survey for willingness to participate. Those interested will be co-managed at the HIV Comorbidities Clinic at the Prince of Wales Hospital, where the DSD model of care is conducted. Evaluation of implementation outcomes will be performed at the end of the programme.",[26,185],"HIV Infections","2024-12-12",{"date":188,"type":54},"2024-12-17",{"date":190,"type":54},"2024-05-01",{"date":192,"type":20},"2026-03-31",{"name":194,"class":61},"Chinese University of Hong Kong"]